Search
Close this search box.

FDA Confirms Safety of AstraZeneca COVID-19 Vaccine for Ghana’s Population

Facebook
Twitter
LinkedIn
WhatsApp
Telegram
Email

The Ghanaian Food and Drugs Authority (FDA) has addressed public apprehensions regarding the AstraZeneca Covid-19 vaccine’s safety after its global recall by the manufacturing company due to an infrequent side effect.

The pharmaceutical company AstraZeneca has recognized a rare but serious condition called Thrombosis with Thrombocytopenia Syndrome (TTS), which has prompted the vaccine’s global discontinuation.

Nonetheless, the Ghana Health Service (GHS) has indicated that the vaccine’s withdrawal is attributed to business considerations and urges the populace to remain calm.

On Tuesday, May 21, 2024, the FDA announced that it has thoroughly examined the adverse events reported post-vaccination (AEFIs) and confirmed the absence of thrombosis with TTS in any of the 4,149 cases reported.

By the conclusion of March 2024, a total of 10,545,038 individuals in Ghana had been administered the AstraZeneca vaccine, according to the FDA.

The FDA reaffirms its commitment to the vigilant oversight of the safety profile of all vaccines in use within Ghana, including those for COVID-19, through its Safety Monitoring Department and the Technical Advisory Committee on Vaccine and Biological Product Safety.

Furthermore, the FDA pledges its dedication to the safeguarding of public health by ensuring the safety, efficacy, and superior quality of all its regulated products, vaccines included.

Share this post :

Facebook
Twitter
LinkedIn
WhatsApp
Telegram
Email